Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.

Abstract

BACKGROUND:

Turosteride (FCE 26073) is a new, potent, and selective 5 alpha-reductase inhibitor. We have investigated its effect on tumor growth, organ weight, and serum hormone levels in rats bearing the androgen sensitive Dunning R3327 prostatic carcinoma.

METHODS:

Animals with tumor diameters of 0.5-1.5 cm were treated for 9 weeks with turosteride (50 and 200 mg/kg/day, 6 days a week, orally), flutamide (25 mg/kg/day, 6 days a week, orally), and leuprolide (300 micrograms/rat, every 3 weeks, subcutaneously) or they were castrated.

RESULTS:

Turosteride was ineffective at the dose of 50 mg/kg/day, whereas at 200 mg/kg/ day it significantly decreased tumor growth by 45%. Flutamide and leuprolide were highly effective in reducing tumor growth (70 and 77%), although their effect was slightly lower than that of castration (85%). A significant reduction of ventral prostate weight occurred in rats treated with turosteride at 50 and 200 mg/kg/day (53% and 60%). In contrast to leuprolide and castration, the inhibitory effect of turosteride on tumor growth and prostate weight was not associated to any decrease in serum testosterone.

CONCLUSIONS:

Turosteride has antitumor activity on Dunning prostatic tumor growth and its role in prostatic cancer treatment is worthy of further investigation.

• Authors: T Zaccheo, D Giudici, E di Salle
• Journal: The Prostate (Prostate) Vol. 30 Issue 2 Pg. 85-91 (Feb 01 1997) ISSN: 0270-4137 [Print] United States
• PMID: 9051146 (Publication Type: Journal Article)

Chemical References

• 5-alpha Reductase Inhibitors
• Antineoplastic Agents, Hormonal
• Enzyme Inhibitors
• Dihydrotestosterone
• Testosterone
• Androstenedione
• Finasteride
• Flutamide
• Luteinizing Hormone
• Leuprolide
• turosteride

Topics

• 5-alpha Reductase Inhibitors
• Adenocarcinoma (drug therapy, pathology)
• Androstenedione (blood)
• Animals
• Antineoplastic Agents, Hormonal (administration & dosage, pharmacology)
• Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use)
• Dihydrotestosterone (blood)
• Enzyme Inhibitors (pharmacology, therapeutic use)
• Finasteride (analogs & derivatives, pharmacology, therapeutic use)
• Flutamide (administration & dosage, pharmacology)
• Leuprolide (administration & dosage, pharmacology)
• Luteinizing Hormone (blood)
• Male
• Organ Size (drug effects)
• Pituitary Gland, Anterior (drug effects)
• Prostate (drug effects)
• Prostatic Neoplasms (drug therapy, pathology)
• Random Allocation
• Rats
• Seminal Vesicles (drug effects)
• Testis (drug effects)
• Testosterone (blood)